文献速递妇科

晚期卵巢恶性肿瘤初次肿瘤细胞减灭术与新辅助化疗联合间歇性肿瘤细胞减灭术的发病率与死亡率荟萃分析

A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
PubMed 文献 · Gynecol Oncol · 2019-07-23

该荟萃分析纳入17项研究共3759例晚期卵巢癌患者,比较初次肿瘤细胞减灭术(PCS)与新辅助化疗联合间歇性肿瘤细胞减灭术(NACT+ICS)的发病率与死亡率。结果显示PCS组Clavien-Dindo≥3级并发症发生率21.2%高于NACT+ICS组的8.8%,PCS组术后30天内死亡风险更高(OR 6.1),NACT+ICS组手术时间更短、失血更少、住院时间更短,且NACT与更高的满意和完全肿瘤细胞减灭率相关,但未带来额外生存获益。

要点

  • PCS组Clavien-Dindo≥3级并发症发生率为21.2%,高于NACT+ICS组的8.8%。
  • PCS组术后30天内死亡风险高于NACT+ICS组(OR 6.1,95%CI 2.1-17.6)。
  • NACT与更高的完全肿瘤细胞减灭率相关(OR 2.2),但未带来额外生存获益(OR 1.0)。

核心结论

  • 与PCS相比,NACT与更低的发病率和死亡率以及更高的完全肿瘤细胞减灭率相关,但无生存获益。
  • 因此,NACT是特定患者(尤其是有内科合并症或高肿瘤负荷者)可接受的替代选择。

研究设计与样本

  • 荟萃分析,检索Cochrane、Medline、Pubmed、Pubmed Central、clinicaltrials.gov和Embase数据库,遵循PRISMA指南。
  • 共审查1341条文献,最终纳入17项研究共3759例患者。
  • 由两名独立评审员应用纳入和排除标准筛选文献,分歧通过共识解决。

主要发现

  • PCS组Clavien-Dindo≥3级并发症总体发生率为21.2%,NACT+ICS组为8.8%(OR 1.9-4.0,p<0.0001)。
  • PCS组术后30天内死亡风险高于NACT+ICS组(OR 6.1,95%CI 2.1-17.6,p=0.0008)。
  • NACT+ICS组手术时间较PCS组缩短(MD -35 min,p=0.01),术中失血更少(MD -382 ml,p<0.001),平均住院时间缩短5.0天(MD -5.0天,95%CI -8.1至-1.9天,p=0.002)。
  • NACT与满意肿瘤细胞减灭率(OR 1.9,95%CI 1.3-2.9,p=0.001)和完全肿瘤细胞减灭率(OR 2.2,95%CI 1.5-3.3,p=0.0001)显著增加相关。
  • NACT未带来额外生存获益(OR 1.0,p=0.76)。

临床怎么用

  • 作者认为,NACT是特定患者(尤其是有内科合并症或高肿瘤负荷者)可接受的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Aim The aim of this meta-analysis is to review the morbidity and mortality associated with primary cytoreductive surgery (PCS) compared to neoadjuvant chemotherapy and interval cytoreductive surgery (NACT + ICS) for advanced ovarian cancer. METHODS: A literature search was performed for publications reporting morbidity and mortality in patients undergoing PCS compared to NACT + ICS. Databases searched were Cochrane, Medline, Pubmed, Pubmed Central, clinicaltrials.gov and Embase. Two independent reviewers applied inclusion and exclusion criteria to select included papers, with differences agreed by consensus. A total of 1341 citations were reviewed; 17 studies comprising 3759 patients were selected for the analysis. The literature search was performed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). RESULTS: Patients in the PCS group were significantly more likely to have a Clavien-Dindo grade ≥ 3 morbidity with an overall rate of 21.2% compared to 8.8% (95%CI 1.9-4.0, p < 0.0001) and were more likely to die within 30 days of surgery (OR 6.1, 95% CI 2.1-17.6, p = 0.0008). Patients who underwent NACT + ICS had significantly shorter procedural times (MD -35 min, p = 0.01), lost less blood intraoperatively (MD-382 ml, p < 0.001) and had an average admission 5.0 days shorter (MD -5.0 days, 95% CI -8.1 to -1.9 days, p = 0.002) than those undergoing PCS. While NACT was associated with significantly increased optimal and complete cytoreduction rates (OR 1.9, 95% CI 1.3-2.9, p = 0.001, and OR 2.2, 95% CI 1.5-3.3, p = 0.0001 respectively), this did not confer any additional survival benefit (OR 1.0, p = 0.76). CONCLUSION: NACT is associated with less morbidity and mortality and improved complete cytoreduction compared to PCS, with no survival benefit. Hence NACT is an acceptable alternative in selected patients in particular with medical co-morbidities or a high tumour burden.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bartels HC, Rogers AC, McSharry V, et al. A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy. Gynecol Oncol. 2019. PMID: 31349996. doi:10.1016/j.ygyno.2019.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。